Edwards Lifesciences CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
Edwards Lifesciences reports increased Q3 sales driven by TAVR and TMTT products, but diluted EPS declined due to higher expenses, impairment charges, and significant litigation and tax disputes.
NYSE
Edwards Lifesciences reported robust sales growth in its core structural heart therapies for Q2 2025, though net income declined due to discontinued operations and increased tax provisions, alongside new legal and regulatory challenges.
NYSE
Edwards Lifesciences' Q1 2025 net sales increased by 6.2% year-over-year, driven by strong performance in Transcatheter Mitral and Tricuspid Therapies (TMTT) and Transcatheter Aortic Valve Replacement (TAVR) product groups.
NYSE
Edwards Lifesciences reported a significant increase in net income for the third quarter of 2024, driven by the sale of its Critical Care business and strong performance in its TAVR and TMTT product lines.
NYSE
10-Q: Edwards Lifesciences Reports Q2 2024 Results, Announces Strategic Divestiture and Acquisitions
Edwards Lifesciences reported a 7.9% increase in net sales for the first six months of 2024, driven by TAVR products, while also announcing the sale of its Critical Care product group and multiple acquisitions.
NYSE
Edwards Lifesciences' first quarter 2024 results show a 9.5% increase in net sales, driven primarily by growth in transcatheter aortic valve replacement (TAVR) products.